CasNo.286930-03-8,Fesoterodinefumarate,(286930-03-8) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99% purity
Payment Terms : T/T,,MoneyGram,Other

Keywords

(R)-Fesoterodine Fumarate 286930-03-8 99% purity

Quick Details

Appearance:White Solid
Application:intermediate
PackAge:According to the need to packing
ProductionCapacity:100|Kilogram|Month
Storage:sealed,dry,low temperature
Transportation:air,sea and courier

Superiority:

Fesoterodinefumarate Basic information

Product Name:   Fesoterodinefumarate
Synonyms:   Fesoterodine maleate;2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate;Propanoic acid, 2-methyl-, 2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) (salt);Spm 8272;Toviaz;Unii-eos72165S7;Fesoterodinefumarate;(R)-Fesoterodine Fumarate
CAS:   286930-03-8
MF:   C30H41NO7
MW:   527.65
EINECS:   639-689-3
Product Categories:   Toviaz;Amines;Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:   286930-03-8.mol

Details:

Fesoterodinefumarate Usage And Synthesis
Chemical Properties   White Solid
Uses   Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. Fesoterodine fumarate (Toviaz) is used to treat the symptoms of overactiv
Uses   (R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS).
Uses   (R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS). It is very similar to Tolterodine (T535800).
Clinical Use   Antimuscarinic:
Symptomatic treatment of urinary incontinence, frequency or urgency
Drug interactions   Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.
Antifungals: dose reduction advised with itraconazole and ketoconazole.
Antivirals: dose reduction advised with atazanavir, indinavir, ritonavir and saquinavir.
Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin, St John's Wort) is not recommended.
Co-administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose reduction to 4 mg may be needed'
See 'Other information'
Metabolism   Molecular weight (daltons) 527.7 % Protein binding 50 (metabolite) % Excreted unchanged in urine 70 (as metabolites) Volume of distribution (L/kg) 169 Litres Half-life - normal/ESRF (hrs) 7 / -